Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007·3.841 Zitationen·Journal of Clinical Oncology
Volltext beim Verlag öffnen3.841
Zitationen
17
Autoren
2007
Jahr
Abstract
To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.
Ähnliche Arbeiten
The Clavien-Dindo Classification of Surgical Complications
2009 · 10.970 Zit.
Radiomics: Images Are More than Pictures, They Are Data
2015 · 7.996 Zit.
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 · 7.614 Zit.
TGF-β SIGNAL TRANSDUCTION
1998 · 7.559 Zit.
Pancreatic Cancer
2000 · 7.244 Zit.
Autoren
Institutionen
Themen
Pancreatic and Hepatic Oncology ResearchNeuroendocrine Tumor Research AdvancesColorectal Cancer Treatments and Studies